Tofacitinib in Psoriatic Arthritis Patients: Skin Signs and Symptoms and Health-related Quality of Life from Two Randomized Phase 3 Studies

Overview

Journal J Eur Acad Dermatol Venereol

Specialty Infectious Diseases

Date 2020 Apr 10

PMID 32271970

Citations 8

Authors

J F Merola

K A Papp

P Nash

J Gratacos

W H Boehncke

D Thaci

D Graham

M-A Hsu

C Wang

J Wu

P Young

Affiliations

Soon will be listed here.

Abstract

Background: Psoriatic arthritis (PsA) is a chronic, systemic immune-mediated inflammatory musculoskeletal disease. The onset of dermatologic symptoms often precedes rheumatic manifestations. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA that has been shown to improve dermatologic symptoms in patients with PsA.

Objectives: To investigate the efficacy of tofacitinib in improving dermatologic endpoints in adult patients with active PsA.

Methods: This analysis included data from two placebo-controlled, double-blind, phase 3 studies in patients with active PsA and an inadequate response (IR) to ≥1 conventional synthetic disease-modifying antirheumatic drug (csDMARD) who were tumor necrosis factor inhibitor (TNFi)-naïve (OPAL Broaden; NCT01877668) or an IR to ≥1 TNFi (OPAL Beyond; NCT01882439). Patients had active plaque psoriasis at screening and received a stable dose of one csDMARD during the study. Patients were randomized to tofacitinib 5 mg twice daily (BID), 10 mg BID, adalimumab 40 mg subcutaneous injection once every 2 weeks (OPAL Broaden only) or placebo (to Month 3). Dermatologic endpoints: Psoriasis Area and Severity Index (PASI) total score; PASI90 overall; PASI75 and PASI90 by baseline PASI severity; Physician's Global Assessment of Psoriasis; Nail Psoriasis Severity Index; Dermatology Life Quality Index total and sub-dimension scores; Itch Severity Item; and Patient's Global Joint and Skin Assessment-Visual Analog Scale-Psoriasis question.

Results: In patients with active PsA, including those stratified by mild or moderate/severe dermatologic symptoms, greater improvements from baseline and percentage of responders were observed in tofacitinib-treated patients vs. placebo for the majority of analyzed dermatologic endpoints at Months 1 and 3, and improvements were maintained to Month 12 in OPAL Broaden and Month 6 in OPAL Beyond. Similar effects were observed in adalimumab-treated patients vs. placebo in OPAL Broaden across dermatologic endpoints.

Conclusions: Tofacitinib provides a treatment option for patients with active PsA, including the burdensome dermatologic symptoms of PsA.

Citing Articles

Tumor necrosis factor (TNF) inhibitors for psoriatic arthritis.

Cagnotto G, Bruschettini M, Strozyk A, Scire C, Compagno M Cochrane Database Syst Rev. 2025; 2:CD013614.

PMID: 39945386 PMC: 11822884. DOI: 10.1002/14651858.CD013614.pub2.

Assessment of the Safety of Tofacitinib Among Patients With Psoriasis: A Systematic Review and Meta-Analysis.

Alqahtani S, Khalil S, Bakhamees B, Almutairi L, Alyahya M, Alghuyaythat W Cureus. 2024; 16(9):e70196.

PMID: 39463512 PMC: 11508819. DOI: 10.7759/cureus.70196.

Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data.

Kristensen L, Deodhar A, Leung Y, Vranic I, Mortezavi M, Fallon L Rheumatol Ther. 2024; 11(3):487-499.

PMID: 38696034 PMC: 11111604. DOI: 10.1007/s40744-024-00662-5.

Skin Anti-Inflammatory Potential with Reduced Side Effects of Novel Glucocorticoid Receptor Agonists.

Flori E, Mosca S, Kovacs D, Briganti S, Ottaviani M, Mastrofrancesco A Int J Mol Sci. 2024; 25(1).

PMID: 38203435 PMC: 10778823. DOI: 10.3390/ijms25010267.

Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study.

Leng X, Lin W, Liu S, Kanik K, Wang C, Wan W RMD Open. 2023; 9(1).

PMID: 36720560 PMC: 9890804. DOI: 10.1136/rmdopen-2022-002559.

References

Lebwohl M, Kavanaugh A, Armstrong A, Van Voorhees A . US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. Am J Clin Dermatol. 2016; 17(1):87-97. PMC: 4733141. DOI: 10.1007/s40257-015-0169-x. View

Singh J, Guyatt G, Ogdie A, Gladman D, Deal C, Deodhar A . Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Care Res (Hoboken). 2018; 71(1):2-29. PMC: 8265826. DOI: 10.1002/acr.23789. View

Bissonnette R, Iversen L, Sofen H, Griffiths C, Foley P, Romiti R . Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. Br J Dermatol. 2014; 172(5):1395-406. DOI: 10.1111/bjd.13551. View

Orbai A, de Wit M, Mease P, Callis Duffin K, Elmamoun M, Tillett W . Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. J Rheumatol. 2017; 44(10):1522-1528. PMC: 5538953. DOI: 10.3899/jrheum.160904. View

Papp K, Menter M, Abe M, Elewski B, Feldman S, Gottlieb A . Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015; 173(4):949-61. DOI: 10.1111/bjd.14018. View

Basra M, Fenech R, Gatt R, Salek M, Finlay A . The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008; 159(5):997-1035. DOI: 10.1111/j.1365-2133.2008.08832.x. View

Mease P, Hall S, FitzGerald O, van der Heijde D, Merola J, Avila-Zapata F . Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. N Engl J Med. 2017; 377(16):1537-1550. DOI: 10.1056/NEJMoa1615975. View

Gladman D . Recent advances in understanding and managing psoriatic arthritis. F1000Res. 2016; 5:2670. PMC: 5115220. DOI: 10.12688/f1000research.9592.1. View

Husni M, Fernandez A, Hauber B, Singh R, Posner J, Sutphin J . Comparison of US patient, rheumatologist, and dermatologist perceptions of psoriatic disease symptoms: results from the DISCONNECT study. Arthritis Res Ther. 2018; 20(1):102. PMC: 5977464. DOI: 10.1186/s13075-018-1601-4. View

10.

Veale D, Fearon U . The pathogenesis of psoriatic arthritis. Lancet. 2018; 391(10136):2273-2284. DOI: 10.1016/S0140-6736(18)30830-4. View

11.

Bachelez H, van de Kerkhof P, Strohal R, Kubanov A, Valenzuela F, Lee J . Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015; 386(9993):552-61. DOI: 10.1016/S0140-6736(14)62113-9. View

12.

Gladman D, Antoni C, Mease P, Clegg D, Nash P . Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005; 64 Suppl 2:ii14-7. PMC: 1766874. DOI: 10.1136/ard.2004.032482. View

13.

Merola J, Shrom D, Eaton J, Dworkin C, Krebsbach C, Shah-Manek B . Patient Perspective on the Burden of Skin and Joint Symptoms of Psoriatic Arthritis: Results of a Multi-National Patient Survey. Rheumatol Ther. 2019; 6(1):33-45. PMC: 6393265. DOI: 10.1007/s40744-018-0135-1. View

14.

Stander S, Luger T, Cappelleri J, Bushmakin A, Mamolo C, Zielinski M . Validation of the Itch Severity Item as a Measurement Tool for Pruritus in Patients with Psoriasis: Results from a Phase 3 Tofacitinib Program. Acta Derm Venereol. 2017; 98(3):340-345. DOI: 10.2340/00015555-2856. View

15.

Ritchlin C, Colbert R, Gladman D . Psoriatic Arthritis. N Engl J Med. 2017; 376(10):957-970. DOI: 10.1056/NEJMra1505557. View

16.

Merola J, Espinoza L, Fleischmann R . Distinguishing rheumatoid arthritis from psoriatic arthritis. RMD Open. 2018; 4(2):e000656. PMC: 6109814. DOI: 10.1136/rmdopen-2018-000656. View

17.

Merola J, Elewski B, Tatulych S, Lan S, Tallman A, Kaur M . Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2017; 77(1):79-87.e1. DOI: 10.1016/j.jaad.2017.01.053. View

18.

Gudu T, Gossec L . Quality of life in psoriatic arthritis. Expert Rev Clin Immunol. 2018; 14(5):405-417. DOI: 10.1080/1744666X.2018.1468252. View

19.

Papp K, Krueger J, Feldman S, Langley R, Thaci D, Torii H . Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol. 2016; 74(5):841-50. DOI: 10.1016/j.jaad.2016.01.013. View

20.

Gladman D, Rigby W, Azevedo V, Behrens F, Blanco R, Kaszuba A . Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. N Engl J Med. 2017; 377(16):1525-1536. DOI: 10.1056/NEJMoa1615977. View